Skip to main content

Tweets

Polycyclic Aromatic Hydrocarbons Increase Lupus Risk A case-controlled study shows environmental exposure to polycyclic aromatic hydrocarbons (PAH) may increase the risk of developing systemic lupus erythematosus (SLE). https://t.co/kztA4s5UY3 https://t.co/QJ6DXXCBh8
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
We're back again on 4/9 with another Tuesday Night Rheumatology! We'll be focusing on PsA Hot Topics. Register to attend today! https://t.co/Ssbv020MOi https://t.co/qL6EGegCVf
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
10 SLE pts w/ ITP and thrombocytopenia were Rx w/ belimumab IV (age 34.3 ± 14 yrs). Overall response rate of thrombocytopenia was 90%, w/ improvement in platelets, lymphocyte count, Hgb, dsDNA, C3, C4 and SLEDAI https://t.co/0IXjqXa8lS https://t.co/pNiu4TCnky
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Among 3.2 million people who starting opioids, there were 506 573 serious fall, esp w/ increasing age; Opioid use associated with increased risk of serious falls, esp. if >85 yrs (adj IRR 6.35) and within the first 28 days of commencing opioid use https://t.co/IifmEE9Q5n https://t.co/N2PkLofA4r
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Oral Surveillance study revisited: the risk of Venous thromboembolism & Pulmonary emboli were higher with tofacitinib (10>5 mg BID) versus TNFi and were generally consistent over time. VTE & PE risk incr by age, BMI, and VTE Hx https://t.co/v7ISjw5Rvd https://t.co/10oE7MiAAj
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
"#RNL2024 Brittany Weber on Cardio-Rheumatology: ""Everything has changed"" on inflammation and CVD - Canakinumab 150 mg v PBO HR 0.85, p =0.02 - Colchicine v PBO HR 0.69, P<0.001 2023: FDA approval for colchicine as 1st anti-inflammatory for reducing CV events

Dr. John Cush @RheumNow ( View Tweet )

1 year 10 months ago
#RNL2024 @RheumNow @Bweber04 Asymptomatic Lupus has higher rate of atherosclerosis at all age grps 35-44 yo F with SLE: 50X increased risk of MI compared to healthy pts in Framingham RA pts at 1.5x risk of CVD https://t.co/wL4U8Gh5JM

Dr. John Cush @RheumNow ( View Tweet )

1 year 10 months ago
#RNL2024 ASCVD Risk Calculators underestimate risk in patients of RA Inflammatory disease was added as a "risk enhancer" in 2019 update "A low ASCVD and/or absence of symptoms may be not be reassuring" https://t.co/Cz1LRda9xx

Dr. John Cush @RheumNow ( View Tweet )

1 year 10 months ago
13 Risk Factors for RA-associated Interstitial Lung Disease (ILD) ILD is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%. https://t.co/oqb37RWPuZ https://t.co/tp3qBh1wRC
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Pearl: Three "S" Rule (Smoking, Seropositivity, Sex/Male): if present the risk of RA-UIP (ILD) goes up nearly 13 fold (ACR23 Abstract 1269) https://t.co/heiTtarS1Y https://t.co/EkHbmMgIEC
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
RCT 302 Dupuytren contracture pts Rx w/ Surgery (n 101), needle fasciotomy (101), or collagenase injx (100). 292 & 284 completed; Success (>50% improved) @3 mos was same: 71%, 73% & 73%. @ 2 yrs, surgery was superior (78% vs. 50% or 65%) https://t.co/K74p1xpnZx https://t.co/xaC4pdPSFQ
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
JAMA: Industry Payments to Physicians ($12.13 billion 2013-22) 1 Ortho: $1,360,744,428 2 Neuro: $1,322,668,751 3 Cardio: $1,293,613,594 4 Heme/onc: $825,799,685 5 Int medicine: $588,249,423 6 Endo: $546,513,674 7 FP: $479,105,369 8 Rheum: $464,858,022 https://t.co/GCWchn9IMz https://t.co/6sRwOWm83y
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
×